Angiotensin Therapeutics, Inc.
Privately held biopharmaceutical company developing engineered recombinant ACE2-based biologics aimed at modulating the renin-angiotensin system for treatment of acute and chronic kidney disease and exploring soluble ACE2 proteins as decoy receptors to prevent SARS-CoV-2 infection. Activities include protein engineering to improve renal targeting and half-life, preclinical efficacy testing in animal models and organoids, and preparation for IND-enabling studies.
Industries
N/A
Products
Short ACE2 variant biologics optimized for kidney delivery
Engineered shortened recombinant ACE2 proteins designed to allow glomerular filtration and provide local renal enzymatic activity to reduce angiotensin II and increase angiotensin-(1-7).
Soluble ACE2 decoy proteins for SARS-CoV-2 neutralization
Soluble ACE2 constructs developed to act as decoy receptors that bind SARS-CoV-2 spike protein and reduce viral entry, tested in cell-based assays, organoids and animal models.
Short ACE2 variant biologics optimized for kidney delivery
Engineered shortened recombinant ACE2 proteins designed to allow glomerular filtration and provide local renal enzymatic activity to reduce angiotensin II and increase angiotensin-(1-7).
Soluble ACE2 decoy proteins for SARS-CoV-2 neutralization
Soluble ACE2 constructs developed to act as decoy receptors that bind SARS-CoV-2 spike protein and reduce viral entry, tested in cell-based assays, organoids and animal models.
Services
Preclinical translational research
Design and execution of preclinical studies to evaluate therapeutic ACE2 variants in kidney disease models and SARS-CoV-2 infection assays.
IND-enabling development planning
Program planning for PK, toxicology, safety pharmacology, genotoxicity and GLP studies to support regulatory filings.
Preclinical translational research
Design and execution of preclinical studies to evaluate therapeutic ACE2 variants in kidney disease models and SARS-CoV-2 infection assays.
IND-enabling development planning
Program planning for PK, toxicology, safety pharmacology, genotoxicity and GLP studies to support regulatory filings.
Expertise Areas
- Therapeutic recombinant protein engineering
- Kidney-targeted biologics development
- Preclinical models of kidney disease (AKI, CKD)
- Antiviral decoy-receptor strategies for SARS-CoV-2
Key Technologies
- Recombinant protein engineering
- Fusion-tag half-life extension
- Molecular-size optimization for glomerular filtration
- Murine disease models (AKI, CKD, SARS-CoV-2)